Theron Stinar, DO
Family Medicine · Fredericksburg, VANPI 1790883866
Payments from drug & device makers
Across 389 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$944
- Novo Nordisk$687
- AstraZeneca$513
- Sanofi-aventis U.S. LLC$477
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$412
- Otsuka America Pharmaceutical, Inc.$365
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,702100%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 61 | $944 |
| Novo Nordisk | 37 | $687 |
| AstraZeneca | 31 | $513 |
| Sanofi-aventis U.S. LLC | 27 | $477 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $412 |
| Otsuka America Pharmaceutical, Inc. | 22 | $365 |
| GSK | 15 | $299 |
| Merck | 21 | $282 |
| Amgen | 15 | $264 |
| Lilly USA, LLC | 16 | $263 |
| Pfizer | 11 | $185 |
| Boehringer Ingelheim | 9 | $180 |
| Lundbeck LLC | 9 | $173 |
| Exact Sciences | 7 | $165 |
| Bayer | 9 | $159 |
| Sunovion Pharmaceuticals Inc. | 11 | $148 |
| Gilead | 5 | $135 |
| Vanda Pharmaceuticals Inc. | 4 | $113 |
| Novartis | 6 | $113 |
| Abbott | 6 | $105 |
| Johnson & Johnson | 6 | $96 |
| Dexcom, Inc. | 4 | $85 |
| Neurocrine Biosciences, Inc. | 3 | $79 |
| Amarin Pharma, Inc. | 4 | $76 |
| Eisai Inc. | 3 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $63 |
| Astellas Pharma US Inc | 3 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $56 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Alk-abello, Inc | 1 | $20 |
| Ardelyx, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $14 |
| Biogen | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
How this compares
$6,732 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $83,442 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 57 | $54,941 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $48,822 |
| FarxigaDapagliflozin Propanediol | 36 | $44,243 |
| JardianceEmpagliflozin | 33 | $40,068 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $29,765 |
| XareltoRivaroxaban | 23 | $24,596 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $21,466 |
| OzempicSemaglutide | 13 | $16,019 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $14,743 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $14,398 |
| LinzessLinaclotide | 13 | $13,029 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $9,913 |
| Ipratropium Bromide | 54 | $2,460 |
| Gabapentin | 82 | $2,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Jardiance | $180 | $95,01090 claims |
| PfizerEliquis | $185 | $83,44276 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $299 | $58,73557 claims |
| AstraZenecaFarxiga | $513 | $44,24336 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $477 | $29,76520 claims |
| Johnson & JohnsonXarelto | $96 | $24,59623 claims |
| Novo NordiskOzempic | $687 | $16,01913 claims |
| AbbVieLinzess | $944 | $13,02913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Fredericksburg
- Dana BrownFredericksburg$21K
- Julie FloydFredericksburg$20K
- Rafael HernandezFredericksburg$18K
- Wilson CookFredericksburg$17K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.